Molnupiravir for SARS-COV-2-infection: utilisation analysis
Page last updated: 14 March 2025
Drug utilisation sub-committee (DUSC)
October 2024
Abstract
Purpose
To review molnupiravir for the treatment of severe acute respiratory syndrome coronavirus 2 (COVID-19) as requested by DUSC at its June 2024 meeting.
Date of listing on the Pharmaceutical Benefits Scheme (PBS)
Molnupiravir was PBS listed on 1 March 2022.
Data Source / methodology
Data extracted from the PBS database maintained by Department of Health and Aged Care, processed by Services Australia were used for the analyses.
Key Findings
- In the first year of PBS listing, 492,941 patients were supplied 509,307 molnupiravir prescriptions. In the second year of PBS listing, 348,052 patients were supplied 361,341 molnupiravir prescriptions.
- Most patients treated with molnupiravir were aged 70 years and older, with the most common age group being those aged between 70-74 years.
- Females accounted for a greater proportion of utilisation compared to males.
- General practitioners accounted for the majority of molnupiravir prescribing.
- Utilisation of molnupiravir in residential aged care facilities account for a small proportion of overall PBS utilisation.
- Molnupiravir has accounted for a greater proportion of the COVID-19 oral antivirals market. However, its market share has decreased over time.
